Skip to main content
Lyrea avatar

Not yet reviewed — this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

Cyclobenzaprine

This article is a stubmissing:
Subjective Effects
Pharmacology
Interactions
Tolerance
History & Culture
Cyclobenzaprine molecule structureCyclobenzaprine molecule structure

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~2 mg
Light2-5 mg
Moderate5-10 mg
Strong10-15 mg
Heavy15+ mg

Duration

Onset15-45 minutes
After Effects1-6 hours
Total6-12 hours

Subjective Effects

Subjective Effects not written up yet

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Marquis(MQ)
white → purple2
Mecke(ME)
white → purple2
Mandelin(MD)
yellow2 → purple2
Liebermann(LB)
white → brown3 → black3
Powered by PROtestkit.eu

Pharmacology

Pharmacology not written up yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Addiction & Dependence

Psychological

Low

Classified as habit-forming, though cyclobenzaprine alone is generally reported to offer limited recreational appeal.

Toxicity

Cardiovascular

Overdose may cause tachycardia and, rarely, cardiac arrest or dysrhythmias; irregular heartbeat is listed as a serious side effect even at therapeutic doses.

Central Nervous System

Common effects include drowsiness, dizziness, and headache at therapeutic doses; overdose or use in elderly patients may cause confusion, delirium, cognitive impairment, tremor, agitation, and ataxia.

Gastrointestinal

Dry mouth occurs commonly at therapeutic doses, with dysphagia reported rarely as a potentially life-threatening side effect.

Psychosis Risk

Hallucinations and confusion are listed as less common manifestations of overdose. Agitation is a common side effect, particularly in elderly patients.

Seizure Risk

Seizures are listed as a rare but potentially critical manifestation of overdose.

History & Culture

History & Culture not written up yet

Legality

By Country

Prescription2
United States flagUnited StatesPrescription only
Canada flagCanadaPrescription only

References

Citations

  1. Prescription Drug List: Human Use. hpr-rps.hres.ca (n.d.). https://hpr-rps.hres.ca/pdl-phu.php1
  2. The Prescription Drug List: Access the list and notices. canada.ca (n.d.). https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/access-list-notices.html1
  3. Food and Drugs Act. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/F-27/section-29.1.html1
  4. Food and Drug Regulations. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.%2C_c._870/section-A.01.010.html1
  5. Food and Drug Regulations. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.%2C_c._870/section-C.01.041.html1
  6. Drug Product Database search results: cyclobenzaprine hydrochloride. health-products.canada.ca (n.d.). https://health-products.canada.ca/dpd-bdpp/search-fast-recherche-rapide?lang=eng&no=01123630011
  7. Product information: CYCLOBENZAPRINE. health-products.canada.ca (n.d.). https://health-products.canada.ca/dpd-bdpp/info?code=77249&lang=eng1
  8. DailyMed - CYCLOBENZAPRINE HYDROCHLORIDE tablet, film coated. dailymed.nlm.nih.gov (n.d.). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a4cc7965-2ba8-42e8-8c5c-b90145a6598a1
  9. DailyMed - FEXMID- cyclobenzaprine hydrochloride tablet. dailymed.nlm.nih.gov (n.d.). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=41838966-de0b-4855-83b8-2ff6c764ed1f1
  10. 21 USC 353: Exemptions and consideration for certain drugs, devices, and biological products. uscode.house.gov (n.d.). https://uscode.house.gov/view.xhtml?req=granuleid%3AUSC-prelim-title21-section353&num=0&edition=prelim1

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed — this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes7 human edits · latest

Times are UTCNewest first

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Cyclobenzaprine article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.